A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies.
More than one third of the world's population living in tropical and subtropical areas of the world is at risk of dengue infections and as many as 100 million people are yearly infected. This disease has reemerged during the past 20 years in the form of an epidemic. Dengue is caused by one of four related serotypes of dengue virus and often leads to severe forms of the disease, resulting commonly from secondary infections. Dengue virus is a mosquito borne virus, belongs to the family Flaviviridae and consists of a single stranded positive sense RNA genome. Like other RNA viruses it escapes defense mechanisms and neutralization attempts by mutations, which make it more resistant and adaptable to its environment. Antiviral strategies and vaccine development is thus impaired and hence to date there is no licensed vaccine available for dengue virus. Here we discuss various efforts made towards the identification of potential vaccine targets for dengue as well as various strategies employed by research groups/pharmaceutical companies towards the development of a successful dengue vaccine.
NUST Center of Virology and Immunology, National University of Sciences and Technology, Islamabad, Pakistan. mohammad_faheem2003@yahoo.com
Muhammad
M
Faheem
Ummar
U
Raheel
Muhammad Nasir
MN
Riaz
Naghmana
N
Kanwal
Farakh
F
Javed
Najam
N
us Sahar Sadaf Zaidi
Ishtiaq
I
Qadri
D003715:Dengue / Q000276:immunology* / Q000821:virology*; D053059:Dengue Vaccines / Q000276:immunology*; D003716:Dengue Virus / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D019444:Vaccines, DNA / Q000276:immunology; D022223:Vaccines, Subunit / Q000276:immunology
D053059:Dengue Vaccines; D019444:Vaccines, DNA; D022223:Vaccines, Subunit